Cardiology Today -- The FDA has expanded indications for olmesartan medoxomil, an angiotensin II receptor blocker, to include children aged 6 to 16 years, after data from a phase-3 trial indicated that it safely and effectively reduced BP in pediatric patients, according to a press release.
